{"id":"NCT00329030","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","briefTitle":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","officialTitle":"Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2006-05-24","resultsPosted":"2016-06-10","lastUpdate":"2021-11-01"},"enrollment":224,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, B-Cell","Lymphoma, Large-Cell, Immunoblastic","Lymphoma, Non-Hodgkin"],"interventions":[{"type":"DRUG","name":"Autologous transplantation using rituxan/BEAM","otherNames":["Rituximab"]},{"type":"DRUG","name":"Autologous transplantation using Bexxar/BEAM","otherNames":["Tositumomab and Iodine I 131 Tositumomab Bexxar"]}],"arms":[{"label":"Rituxan/BEAM","type":"ACTIVE_COMPARATOR"},{"label":"Bexxar/BEAM","type":"EXPERIMENTAL"}],"summary":"This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus BEAM transplant regimen versus a regimen adding Bexxar to BEAM.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"1 and 2 years","effectByArm":[{"arm":"B-BEAM","deltaMin":53.2,"sd":null},{"arm":"R-BEAM","deltaMin":56.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":12},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["23478060"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":111},"commonTop":[]}}